OBJECTIVE: The aim of this study was to confirm the most appropriate dosage of a new soft gelatin capsule (SGC) formulation of the HIV protease inhibitor saquinavir by investigating the relationships between systemic (plasma) exposure to saquinavir and plasma HIV RNA and CD4+ cell counts using empirical mathematical modelling. DESIGN AND SETTING: A randomised, non-blind, multicentre, dose-ranging 8-week study of monotherapy with 400, 800 or 1200 mg of saquinavir-SGC or 600 mg of the hard gelatin capsule (HGC) formulation, both administered 3 times daily, was carried out in protease inhibitor-naive, HIV-positive adults. Two surrogate markers of response, plasma HIV RNA level and CD4+ cell count, were fitted to 2 measures of systemic drug exposure, the area under the plasma concentration-time curve (AUC) and trough plasma concentration (Cmin), using 6 exposure-response models of progressively increasing complexity. Akaike and Schwarz model selection criteria were applied to determine the most effective pharmacokinetic-pharmacodynamic relationship. RESULTS: A total of 88 patients were randomised; pharmacokinetic and pharmacodynamic data were available for 84 patients. In terms of plasma HIV RNA, pharmacokinetic-pharmacodynamic relationships were best described by a 2-parameter maximum effect (Emax) model, which predicted a typical maximum reduction in viral load of 1.94 log10 copies/ml [coefficient of variation (CV) 12%], with a half-maximal antiviral response occurring at a Cmin of 50 micrograms/L (CV 40%). Saquinavir-SGC 1200 mg administered 3 times daily produced a median AUC to 24 hours (AUC24) of approximately 20,000 micrograms/L.h, corresponding to 85% of the maximum achievable antiviral effect as defined by the model. None of the models yielded a satisfactory fit for CD4+ cell count. CONCLUSION: Empirical mathematical modelling confirmed that, when administered 3 times daily, the optimum dose of saquinavir-SGC is 1200 mg, corresponding to 3600 mg/day.
RCT Entities:
OBJECTIVE: The aim of this study was to confirm the most appropriate dosage of a new soft gelatin capsule (SGC) formulation of the HIV protease inhibitor saquinavir by investigating the relationships between systemic (plasma) exposure to saquinavir and plasma HIV RNA and CD4+ cell counts using empirical mathematical modelling. DESIGN AND SETTING: A randomised, non-blind, multicentre, dose-ranging 8-week study of monotherapy with 400, 800 or 1200 mg of saquinavir-SGC or 600 mg of the hard gelatin capsule (HGC) formulation, both administered 3 times daily, was carried out in protease inhibitor-naive, HIV-positive adults. Two surrogate markers of response, plasma HIV RNA level and CD4+ cell count, were fitted to 2 measures of systemic drug exposure, the area under the plasma concentration-time curve (AUC) and trough plasma concentration (Cmin), using 6 exposure-response models of progressively increasing complexity. Akaike and Schwarz model selection criteria were applied to determine the most effective pharmacokinetic-pharmacodynamic relationship. RESULTS: A total of 88 patients were randomised; pharmacokinetic and pharmacodynamic data were available for 84 patients. In terms of plasma HIV RNA, pharmacokinetic-pharmacodynamic relationships were best described by a 2-parameter maximum effect (Emax) model, which predicted a typical maximum reduction in viral load of 1.94 log10 copies/ml [coefficient of variation (CV) 12%], with a half-maximal antiviral response occurring at a Cmin of 50 micrograms/L (CV 40%). Saquinavir-SGC 1200 mg administered 3 times daily produced a median AUC to 24 hours (AUC24) of approximately 20,000 micrograms/L.h, corresponding to 85% of the maximum achievable antiviral effect as defined by the model. None of the models yielded a satisfactory fit for CD4+ cell count. CONCLUSION: Empirical mathematical modelling confirmed that, when administered 3 times daily, the optimum dose of saquinavir-SGC is 1200 mg, corresponding to 3600 mg/day.
Authors: S Vella; A Lazzarin; G Carosi; A Sinicco; O Armignacco; G Angarano; M Andreoni; G Tambussi; A Chiodera; M Floridia; S Scaccabarozzi; K Facey; I Duncan; P Boudes; K Bragman Journal: Antivir Ther Date: 1996-08
Authors: G F Vanhove; J M Gries; D Verotta; L B Sheiner; R Coombs; A C Collier; T F Blaschke Journal: Antimicrob Agents Chemother Date: 1997-11 Impact factor: 5.191
Authors: F de Wolf; I Spijkerman; P T Schellekens; M Langendam; C Kuiken; M Bakker; M Roos; R Coutinho; F Miedema; J Goudsmit Journal: AIDS Date: 1997-12 Impact factor: 4.177
Authors: R T Mitsuyasu; P R Skolnik; S R Cohen; B Conway; M J Gill; P C Jensen; J J Pulvirenti; L N Slater; R T Schooley; M A Thompson; R A Torres; C M Tsoukas Journal: AIDS Date: 1998-07-30 Impact factor: 4.177
Authors: A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey Journal: N Engl J Med Date: 1996-04-18 Impact factor: 91.245
Authors: J M Schapiro; M A Winters; F Stewart; B Efron; J Norris; M J Kozal; T C Merigan Journal: Ann Intern Med Date: 1996-06-15 Impact factor: 25.391
Authors: T N Kakuda; L M Page; P L Anderson; K Henry; T W Schacker; F S Rhame; E P Acosta; R C Brundage; C V Fletcher Journal: Antimicrob Agents Chemother Date: 2001-01 Impact factor: 5.191
Authors: Alan Maloney; Marloes Schaddelee; Jan Freijer; Walter Krauwinkel; Marcel van Gelderen; Philippe Jacqmin; Ulrika S H Simonsson Journal: J Pharmacokinet Pharmacodyn Date: 2010-09-25 Impact factor: 2.745
Authors: José Moltó; Asunción Blanco; Cristina Miranda; José Miranda; Jordi Puig; Marta Valle; Meritxell Delavarga; Carmina R Fumaz; Manuel José Barbanoj; Bonaventura Clotet Journal: Br J Clin Pharmacol Date: 2007-01-12 Impact factor: 4.335
Authors: Saye H Khoo; Patrick G Hoggard; Ian Williams; E Rhiannon Meaden; Philippa Newton; Edmund G Wilkins; Alan Smith; John F Tjia; Judy Lloyd; Kevin Jones; Nick Beeching; Peter Carey; Barry Peters; David J Back Journal: Antimicrob Agents Chemother Date: 2002-10 Impact factor: 5.191
Authors: Marta Boffito; Patrick G Hoggard; Helen E Reynolds; Stefano Bonora; E Rhiannon Meaden; Alessandro Sinicco; Giovanni Di Perri; David J Back Journal: Br J Clin Pharmacol Date: 2002-09 Impact factor: 4.335